Methotrexat Sandoz

Methotrexate, the active ingredient in Methotrexat Sandoz, is an antimetabolite presented as a sterile injectable solution for intramuscular, intrathecal, and intravenous use. It interferes with cell proliferation and is employed in the treatment of certain cancers, autoimmune disorders, and trophoblastic diseases.

GNH USA supplies Methotrexat Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation, cold‑chain logistics where required, and responsive customer support to meet the needs of global healthcare providers.

Methotrexate is used in several oncologic and immune‑mediated disease pathways to inhibit abnormal cell growth. - Acute lymphoblastic leukemia: induces remission by blocking DNA synthesis in rapidly dividing lymphoblasts. - Non‑Hodgkin lymphoma: reduces tumor burden through antiproliferative effects on malignant lymphocytes. - Rheumatoid arthritis: decreases joint inflammation and damage by suppressing immune cell activity. - Psoriasis: slows skin cell turnover, leading to improvement of plaques. - Gestational trophoblastic disease: eradicates trophoblastic tissue by interfering with folate metabolism.

Methotrexate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea or vomiting: gastrointestinal upset commonly reported. - Fatigue: persistent tiredness or weakness. - Mouth sores: ulceration of oral mucosa. - Elevated liver enzymes: mild hepatic transaminase rise.

Serious or Rare Side Effects: - Bone marrow suppression: pancytopenia leading to infection risk. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Severe hepatotoxicity: progressive liver fibrosis or cirrhosis.

When prescribing methotrexate, clinicians should observe several safety precautions to minimize toxicity. - Renal function: assess baseline creatinine and adjust dose in impairment. - Hepatic monitoring: perform regular liver function tests during therapy. - Pregnancy avoidance: contraindicated in pregnancy due to teratogenic risk. - Concomitant folate: supplement with folic acid to reduce mucosal and hematologic toxicity. - Drug interactions: review for NSAIDs, sulfonamides, and other myelosuppressive agents. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate interacts with several medicines that can alter its efficacy or safety profile.

Major Interactions (Avoid): - NSAIDs (e.g., ibuprofen, naproxen): increase risk of renal toxicity and delayed methotrexate clearance. - Proton pump inhibitors (e.g., omeprazole): may reduce renal elimination, raising serum levels. - Sulfonamide antibiotics (e.g., trimethoprim‑sulfamethoxazole): potentiate myelosuppression.

Moderate Interactions (Monitor Closely): - Azathioprine or cyclophosphamide: additive immunosuppression requiring blood count monitoring. - Live vaccines: risk of infection due to immunosuppression. - Vitamin B12 or folate supplements: may diminish therapeutic effect at high doses.